Randox Signs Principal Partnership with Sheffield United FC

Home - Randox - Page 6

Randox Signs Principal Partnership with Sheffield United FC

COVID-19 Testing        News        Contact Us

26th May 2021 – Randox Signs Principal Partnership with Sheffield United FC 

Global innovative healthcare company and the UK’s largest COVID-19 PCR testing provider Randox is today pleased to announce that it has signed a three-year principle partnership agreement with Sheffield United. The partnership will commence in the 2021 /2022 season and will include both men’s and women’s first team. From next season both teams will wear the Randox logo on their jerseys.

Founded in 1982 in County Antrim by leading medical scientist, Dr. Peter FitzGerald‎ CBE, Randox has been a pioneer in improving health and enhancing lives, worldwide. To achieve their goals the company is committed to an extensive research programme, including  investing more than £300m in the development of its innovative biochip array programme to enable earlier, more accurate diagnosis. The company currently employs more than 2000 people of over 40 different nationalities.

Randox is a world leader in healthcare diagnostics; today more than 5% of the world’s population – in excess of 370 million people across 145 countries – receives medical diagnosis through use of Randox products each year. Over the past year, Randox has been at the forefront of the UK’s fight against COVID-19, and has significantly invested in its testing capacity meaning that it can now process over 500,000 tests per day, making it amongst the very largest COVID-19 laboratories in Europe.  To date Randox having processed over 13 million COVID-19 PCR tests in the UK and now have comprehensive Covid-19 testing, logistics and customer services available to support overseas holidays and those undertaking international travel.

Randox has a proud history of supporting sports, and has been the Official Partner of the, the Grand National since 2017.

Dr. Peter FitzGerald‎ CBE, Randox Chief Executive Officer, said;

“We are very excited about this partnership and the opportunity to align Randox with Sheffield United Football Club. Not only is Sheffield the birthplace of football, but it is also one of the fastest growing cities in developing sports science and medical technology which we are very keen to see how we can look to assist through our services. We are extremely proud to be the principal partner of the Blades and to be a part of the club’s progress in the years to come.”

For press enquiries please contact Amy Millar in the Randox PR team on amy.millar@randox.com or 028 9442 2413

Sheffield United

Want to know more?

Contact us or visit Randox Health.

Related COVID-19 Products and Services

HOME TEST

ANTIBODY TEST

TEST TO RELEASE

LABORATORY TOOLS


Neonatal Bilirubin External Quality Assessment

The RIQAS Neonatal Bilirubin EQA programme has been designed to assess the performance of total and direct bilirubin assays with levels tailored to neonatal bilirubin testing.

  • Lyophilised for enhanced stability
  • Monthly reporting
  • Human based serum
  • Submit results and view reports online via RIQAS.net
  • Rapid turnaround of reports allows for any necessary corrective actions to be taken with minimal disruption to laboratory output

Not accredited to ISO/IEC 17043

Cat NoKit SizeFrequencyCycle StartParameters
RQ91912 x (6x3ml)MonthlyJuly2

Parameter

  • Direct Bilirubin
  • Total Bilirubin

Please note, product availability may vary country to country.


The Silent Diabetes Pandemic: A Randox Reagents Blog

The Silent Pandemic

A striking statistic is that an estimated 4.2 million people die annually from Diabetes complications and it is anticipated it will be the seventh leading cause of death by 2030.

Type 2 diabetes mellitus (T2DM) has reached the status of  ‘global  pandemic’, a phrase we have become all too familiar with due to the current global Covid-19 pandemic, but one we now know not take for granted.

Diabetes is a chronic, potentially life-threatening disease and can cause a myriad of health complications which affect the feet, eyes, kidneys, and cardiovascular health.

Early detection and treatment of diabetes is key, particularly as many people with type 2 diabetes have no signs or symptoms but do have associated risk factors.

Randox is committed to raising awareness of preventative healthcare related to Diabetes through advancing diabetes testing capabilities, including diabetes diagnosis & monitoring, and monitoring of associated complications including; ketoacidosis, renal dysfunction, and metabolic status.

The Randox Diabetes testing panel consists of ten assays including niche and superior performance assays that are compatible with a wide range of clinical chemistry analyzers.

Contact Us

Find out more about the Randox diabetes reagents panel or alternatively you can contact us

reagents@randox.com | www.randox.com/diabetes-reagents

Product availability may vary from country to country. Some products may be for research use only. For more information on product application & availability, please contact your local Randox Representative


The Importance of Third-Party Controls #LABWEEK2021

 

In the clinical laboratory, Quality Control (QC) refers to the process of detecting analytical errors to ensure both the reliability and accuracy of patient test results. Poor performance can result in misdiagnosis, delayed/inappropriate treatment, increased costs and may even be potentially life threatening for the patient. Third party controls offer a better solution to ensure optimum performance and accuracy.

When the laboratory professional runs the QC material on their instrument, they can compare the obtained result with the expected result. If these values are comparable, then the laboratory professional can be confident that their instrument is reporting accurately. Essentially, QC is a ‘practice run’ to ensure the testing system is working correctly.

Benefits Of Using Third-Party Controls

Third party controls have been designed to deliver an independent, unbiased assessment of performance with any instrument or method helping you gain accreditation. Below are some of the key benefits of third party controls:

  • Values assigned using a large number of independent laboratories ensuring statistically valid targets.
  • Highly consolidated controls allow for space, time, and ultimately, cost savings.
  • Boosted shelf life ensures continuity of supply and reduced costs
  • Reduced preparation times by removing the need for multiple instrument controls

Importance Of Third-Party Controls In The Midst Of COVID-19

Quality Control is a hugely important part of laboratory quality. Around 70% of clinical decisions are made based on laboratory results, so it is plain to see how significant Quality Control practices can be in relation to global health care. Having faith in the performance of the Quality Control used within the lab, as well as benefits gained from highly consolidated controls, allow for space, time, and ultimately, cost savings. These benefits would prove highly beneficial for any laboratory operating in the fast-paced environment posed by the pandemic.

How Randox Can Help

Randox Acusera true third party quality controls offer complete test menu consolidation for laboratory Internal Quality Control. Providing accurate and reliable sample material and delivering results you can trust.

Find out more: https://www.randox.com/laboratory-quality-control-acusera/

Want to know more?

Contact us or visit our Acusera page to learn more.

Related Products

Serology Controls

Acusera Controls

RIQAS EQA

Resource Hub


Evidence Series Resource Hub

Evidence Series | Resource Hub

  • Brochures
  • Flyers
  • Videos
  • Blogs
  • Scientific Posters
  • Whitepapers

Evidence

Evidence Investigator

Evidence MultiSTAT

Evidence+

Evidence Evolution

Biochip Technology Explained

Evidence series Overview

Discover more about the Evidence series

 

Cytokines Flyer

DIKI Renal Flyer

A4 Renal Flyer

AKI Covid-19 Flyer

Evidence Investigator - Molecular Diagnostic Testing

Evidence MultiSTAT Demonstration

Evidence Evolution - World's Most Advanced Immunoanalyser

Evidence Investigator - Myco 9 Array, Step By Step

No related posts.

DEVELOPMENT OF A BIOCHIP ARRAY FOR THE SIMULTANEOUS DETECTION OF CANCER BIOMARKERS ON THE RANDOM ACCESS, FULLY AUTOMATED EVIDENCE EVOLUTION ANALYSER

DEVELOPMENT OF A DUPLEX BIOCHIP ASSAY FOR THE SIMULTANEOUS DETECTION OF ANTI-THYROGLOBULIN AND ANTI-THYROID PEROXIDASE ANTIBODIES ON THE FULLY AUTOMATED EVIDENCE EVOLUTION ANALYSER

DEVELOPMENT OF NEW BIOCHIP ARRAYS FOR THE DETERMINATION OF BIOMARKERS RELATED TO ACUTE KIDNEY INJURY APPLIED TO THE EVIDENCE INVESTIGATOR ANALYSER

DEVELOPMENT OF A NEW BIOCHIP BASED IMMUNOASSAY FOR THE DETECTION OF PARATHYROID HORMONE APPLIED TO THE EVIDENCE EVOLUTION ANALYSER

DEVELOPMENT OF A HIGHLY MULTIPLEXED MOLECULAR ASSAY FOR DETECTION OF INFECTION IN CF AIRWAYS

Repeatability and within-laboratory precision were assessed (n=80): Assay Repeatability Within-laboratory precision CV (%) CV (%) VCAM-1 4.5 6.8 ICAM-1 5.6 8.8 ESEL 12.8 16.6 PSEL 3.5 4.7 LSEL 5.7 8.2 17.096, 097.105RDRT DEVELOPMENT OF A BIOCHIP ARRAY FOR THE DETECTION OF ADHESION MOLECULES ON THE NEW RANDOM ACCESS FULLY AUTOMATED EVIDENCE EVOLUTION ANALYSER

DEVELOPMENT OF A NEW BIOCHIP BASED IMMUNOASSAY UNAFFECTED BY DHEA-S INTERFERENCE FOR THE ACCURATE MEASUREMENT OF SERUM PROGESTERONE

DEVELOPMENT OF A BIOCHIP ARRAY FOR THE RAPID, SIMULTANEOUS DETECTION OF PEPSINOGEN I, PEPSINOGEN II AND GASTRIN 17, ON THE NEW RANDOM ACCESS, FULLY AUTOMATED EVIDENCE EVOLUTION ANALYSER

CLINICAL EVALUATION OF A RAPID FULLY-AUTOMATED MULTIPLEX BIOCHIP ARRAY FOR STROKE DIAGNOSIS

DEVELOPMENT OF A NEW BIOCHIP ARRAY APPLIED TO THE NEW RANDOM ACCESS FULLY AUTOMATED EVIDENCE EVOLUTION ANALYSER FOR THE SIMULTANEOUS MEASUREMENT OF TSH, FREE T4 AND FREE T3

DEVELOPMENT OF A NEW BIOCHIP BASED IMMUNOASSAY FOR THE MEASUREMENT OF TOTAL 25-HYDROXYVITAMIN D IN SERUM AND THE ACCURATE CLASSIFICATION OF VITAMIN D STATUS

DEVELOPMENT OF A BIOCHIP ASSAY FOR THE DETECTION OF THYROXINE-BINDING GLOBULIN (TBG) ON THE NEW RANDOM ACCESS FULLY AUTOMATED EVIDENCE EVOLUTION ANALYSER

GENETIC DIAGNOSIS OF MONOGENIC OR POLYGENIC FAMILIAL HYPERCHOLESTEROLEMIA IN NORTHERN IRELAND: EVALUATION OF THE RANDOX FH ARRAYS IN COMBINATION WITH THE RANDOX 6SNP POLYGENIC HYPERCHOLESTEROLEMIA ARRAY

DEVELOPMENT OF A BIOCHIP ARRAY FOR THE SIMULTANEOUS MEASUREMENT OF DISTINCT FATTY ACID-BINDING PROTEINS (FABPs)

DEVELOPMENT OF A NEW ENZYME-LINKED IMMUNOSORBENT ASSAY KIT TO DETECT NGAL IN HUMAN SERUM AND ITS APPLICATION TO CHRONIC KIDNEY DISEASE

SCREENING AND SELECTION OF ANTIBODIES FOR THE DETECTION OF MIP-1 ALPHA AND ITS APPLICATION TO THE STUDY OF CHRONIC KIDNEY DISEASE

DEVELOPMENT OF A 4-PLEX BIOCHIP ARRAY FOR THE EARLY DETECTION OF CHRONIC KIDNEY DISEASE

DEVELOPMENT OF A THIRD GENERATION TSH ASSAY ON THE NEW RANDOM ACCESS EVIDENCE EVOLUTION FULLY AUTOMATED BIOCHIP ANALYSER

APPLICATION OF THE NEW RANDOM ACCESS, FULLY AUTOMATED BIOCHIP ANALYSER EVIDENCE EVOLUTION TO SIMULTANEOUSLY MEASURE ANALYTES RELATED TO ENDOCRINE FUNCTION

STRATIFYING RISK OF ACUTE KIDNEY INJURY IN PRE AND POST CARDIAC SURGERY PATIENTS USING A NOVEL BIOMARKER-BASED ALGORITHM AND CLINICAL RISK SCORE

SARS-CoV-2 Vascular & Multi-System Dysfunction

Acute Kidney Injury and Antimicrobial Stewardship


Banned substance furazolidone (AOZ) detected in shrimp at French border

randox-food-diagnostics

About RFD        News        Contact Us

14 April 2021: Banned substance furazolidone (AOZ) detected in shrimp at French border

As per an alert through RASFF – the Rapid Alert System for Food and Feed for the EU, shrimp imported from India has been rejected at the French border in March 2021 for containing a banned substance, known as furazolidone (AOZ). The shrimp product has since been destroyed and did not make it into the market for distribution.

Nitrofuran antibiotics, the parent compound of AOZ, were banned for use in animal food production in the EU in 1995 and 2009 in the US for its reported carcinogenic and mutagenic characteristics. However due to the drugs low cost and effectiveness in controlling disease it is still in use despite the ban.

Randox Food Diagnostics

Randox Food Diagnostics have developed a highly accurate and reliable immunoassay array which detects Nitrofuran residues including AOZ, AMOZ, AHD and SEM.

Available on the Evidence Investigator, our Antimicrobial Array III utilises our patented Biochip Array Technology which provides screening of up to 54 meat and seafood samples. The Evidence Investigator provides results for multiple drug residues and toxins in just 2.5 hours, saving the user both time and money compared to other screening and confirmatory methods.

Randox Food Diagnostics also provide a vast variety of ELISA kits to test for antibiotics in meat and seafood tissue, offering excellent cross-reactivity and unrivalled limits of detection. With results providing great correlation with confirmatory methods, we ensure that better science means safer food.

Want to know more?

For more information on tissue screening methods from Randox Food Diagnostics please visit the links below.

www.randoxfood.com/meat-and-seafood-analysis/

Alternatively contact us via email: info@randoxfooddiagnostics.com

Want to know more?

Contact us or visit our Randox Food Diagnostics website.

Related Products

Meat & Seafood

Milk

Honey

Wine


World Kidney Day 2021

World Kidney Day 2021

11th March 2021 is World Kidney Day, a worthy global campaign aimed at tackling “the hot topic everyone’s ignoring”.

Raising awareness of a disease that ‘one in every nine’ people worldwide suffer from, is something we take seriously.

Here at Randox, our vision is to improve healthcare worldwide and ensure patients across the globe have access to the latest advancements in clinical diagnostics to tackle diseases such as Chronic Kidney Disease.

This year World Kidney Day 2021 focuses on being able to live well with kidney disease. Many of us take for granted being able to live a normal life without the side effects such as fatigue, pain, depression, sleep problems etc. However Kidney disease can be huge challenge patients and those around them. The impacts of kidney disease can take a toll of day to day life and the ability to participate in activities such as work, travel, and socialising.

Kidney diseases are very common and can be harmful, but the good news is they are also very treatable!

Randox offer a comprehensive panel of kidney health tests, working to ensure timely and accurate diagnosis of kidney function problems to combat patient challenges early.

For example, low levels of albumin indicate signs of kidney damage in the early stages when diagnosis is key. Testing for albumin can identify individuals with diabetic nephropathy (damage to the kidneys caused by diabetes) around 10 years earlier than standard protein tests. The Randox albumin test can therefore enable preventative measures to be taken to reduce your risk of developing kidney disease.

With early diagnosis we can improve patient treatment outcomes and reduce the number of people across the world suffering with kidney health problems.

If you are a clinician or lab interested in running renal function assays, download our Reagents Brochure or email reagents@randox.com

If you want to find out the status of your own Kidney Health, book a health check with Randox Health today.

 

 

Want to know more about Randox?

Contact us or visit our homepage to view more.


Dog Food Recalled Due to Potentially Unsafe Levels of Aflatoxin

randox-food-diagnostics

About RFD        News        Contact Us

Dog Food Recalled Due to Potentially Unsafe Levels of Aflatoxin

The importance of screening food for toxins has been highlighted this month with the recent news that Midwestern Pet Foods Inc. have extended their product recall after reports that the pet food has potentially caused the deaths of 70 dogs due to containing possibly unsafe levels of aflatoxin.

The Food and Drug Administration said in a statement that it has been “aware of more than 70 dogs that have died and more than 80 that are sick after eating Sportmix pet food.”

Aflatoxins are mycotoxins produced by two species of Aspergillus, a fungus which is especially found in areas with hot and humid climates. Aflatoxins have a wide occurrence in feed and cereals, such as wheat, barley, rice and corn, which are used as ingredients in pet food. At high levels, aflatoxin can cause illness and death in animals.

Midwestern Pet Foods first announced a voluntary recall on Dec. 30, extending it last week. “There have been reports of illnesses and deaths in dogs associated with certain lots of products. No human illnesses have been reported,” the company said in a recall announcement. “Out of an abundance of caution, we have expanded this recall to cover all corn products containing pet foods with expiration dates prior to 07/09/22.”

Aflatoxin poisoning can display in animals with symptoms such as sluggishness, loss of appetite, vomiting, jaundice and diarrhoea.

The expanded recall includes “additional corn-containing lot codes of Sportmix, Pro Pac Originals, Splash, Sportstrail, and Nunn Better dry dog and cat foods” that were produced in its Oklahoma manufacturing plant. A full list of recalled products can be found here.

Randox Food Diagnostics

Randox provide solutions to the agricultural industry by having developed a range of screening platforms for toxins and drug residues within feed and cereals. Multiple mycotoxins can affect crops and drug residues can pass through to feed causing adverse health effects in both humans and animals.

Myco 9 facilitates the detection of up to 9 common mycotoxins from a single sample of cereal or cereal based feed, including aflatoxin B1/B2, aflatoxin G1/G2, deoxynivalenol, diacetoxyscirpenol, fumonisins, ochratoxin A, paxilline, T2 toxin & zearalenone.

For more information on the antibiotic screening arrays available contact us at: info@randoxfooddiagnostics.com

 

Want to know more?

Contact us or visit our Randox Food Diagnostics website.

Related Products

Meat & Seafood

Milk

Honey

Wine


Randox unveils SARS-CoV-2 antibody test to determine previous COVID-19 infection in just 1.5 hours

   

21st December 2020

Randox unveils SARS-CoV-2 antibody test to determine previous COVID-19 infection in just 1.5 hours

Randox Laboratories is proud to announce the launch of its new SARS-CoV-2 IgG test, utilising patented Randox Biochip Technology to simultaneously detect IgG antibodies that are reactive to both of the leading COVID-19 diagnostic antigens – Spike Receptor Binding Domain (RBD) and Nucleocapsid protein (NP).

Maximum test sensitivity is ensured through simultaneous detection of both RBD-only and NP-only responders, making it superior to current commercially available COVID-19 IgG tests that are based on RBD or NP alone, from which false negative results can occur.

The Randox SARS-CoV-2 IgG (RBD & NP) Array provides clinicians with an opportunity to discriminate vaccinated individuals from those naturally infected by COVID-19.

Lynsey Adams, Randox Clinical Marketing Manager commented;

“When there is little or no access to molecular testing, serology tests provide a means to quickly triage suspected cases of COVID-19, enabling appropriate case management, and guiding public health measures, such as quarantine or self-isolation.

 “The new Randox SARS-CoV-2 IgG (RBD & NP) Array, provides a unique insight into disease severity, is an established method of indirect disease diagnosis, and facilitates epidemiological surveillance as the COVID-19 pandemic progresses.”

 The Randox SARS-CoV-2 IgG (RBD & NP) Array has been developed for the Evidence Investigator, a semi-automated benchtop immunoassay analyser delivering accurate results in just 1.5 hours.

Features of the new Randox SARS-CoV-2 IgG (RBD & NP) Array

  • Utilises established diagnostic antigen candidates – RBD and NP
  • IgG measurement confirms adaptive immune response to SARS-CoV-2
  • Clinical specificity of 99.5%
  • Clinical sensitivity of 100% ≥ 14 days post SARS-CoV-2 PCR confirmation
  • Dual sample matrix: human serum/plasma.

Contact marketing@randox.com for further information on our latest SARS-CoV-2 array or click to find out more!

Randox in the media

Latest News

FAQs


Vivalytic’s rapid coronavirus test delivers results for positive samples in less than 30 minutes

   

18th December 2020

Cloud-based software update means a faster PCR test for SARS-CoV-2

We are happy to announce that due to improved software for the Vivalytic analysis device, the CE marked Vivalytic SARS-CoV-2 rapid coronavirus test, which uses polymerase chain reactions (PCR), now delivers its results even faster. By applying optimized evaluation strategies, the Vivalytic analysis device can detect a positive SARS-CoV-2 sample through its high viral load in less than 30 minutes, right where the sample is collected.

This modified product is part of a research and development project relating specifically to COVID-19, funded by the German Federal Ministry of Education and Research (BMBF) to the tune of 4.97 million euros. The project’s aim is to expand the options for detecting acute infections of the coronavirus, looking particularly at on-the-spot testing in which the sample is analyzed in a fully automatic PCR process, as this offers rapid yet reliable results.

  • Improved software for Vivalytic: turnaround time for positive SARS-CoV-2 samples reduced to under 30 minutes.
  • Update from the cloud: Vivalytic analysis devices are updated over the internet.

Dr. Volkmar Denner, chairman of the board of management of Robert Bosch GmbH said;

“In the fight to contain the coronavirus pandemic, speed is of the essence. With Vivalytic, we are delivering cutting-edge medical technology. Our IT and software expertise have helped to make the Bosch Corona test for positive samples even faster – all within a short period of time.”

The new update is available for the SARS-CoV-2 singleplex test and the SARS-CoV-2 pooled test. Updating the Vivalytic testing devices is simple and straightforward – all that is required is an internet connection to access the Bosch cloud platform Vivasuite. Developed in-house at Bosch, the Vivasuite cloud platform allows users to digitally manage and update all their Bosch Healthcare Solutions devices. This is also an advantage when Vivalytic devices are in use in the field. The platform meets the strictest security standards and data privacy is guaranteed at all times: for example, there is no remote access to Vivalytic devices, and no possibility of accessing patient data.

The turnaround time for samples negative for SARS-CoV-2 is still 39 minutes. PCR tests are considered the gold standard, and Bosch’s rapid coronavirus tests have a sensitivity of 98 percent and a specificity of 100 percent.

Contact marketing@randox.com for further information on the latest vivalytic software update for SARS-CoV-2 testing. 

Randox in the media

Latest News

FAQs


Request a meeting
×
Make an Enquiry - RX series
×
Make an Enquiry - Reagents